<DOC>
	<DOCNO>NCT00131469</DOCNO>
	<brief_summary>The purpose study determine effectiveness teriparatide ( FORTEO ) , human parathyroid hormone 1-34 , increase bone mass improve bone structure adult affect Osteogenesis Imperfecta ( OI ) .</brief_summary>
	<brief_title>Study Teriparatide ( FORTEO ) Treat Adults With Osteogenesis Imperfecta</brief_title>
	<detailed_description>The purpose study determine effectiveness teriparatide ( FORTEO ) , human parathyroid hormone 1-34 , increase bone mass improve bone structure adult affect Osteogenesis Imperfecta ( OI ) . Osteogenesis imperfecta inherit disorder type I collagen , major component bone , characterize multiple fracture deformity . OI affect approximately 1-2 every 10,000 individual . Virtually study potential treatment OI evaluate effect medication child OI . There cure osteogenesis imperfecta establish medical therapy adult disorder . There limited data concern usefulness parathyroid hormone therapy OI . An effective anabolic therapy treatment adult patient OI could valuable asset affected patient . In study , work hypothesis individual affect OI treat Forteo experience increase spine hip bone mineral density increase bone strength . Although Forteo expect change defect collagen produce , postulated increase quantity bone form improve bone strength . This placebo control , double blinded trial ; half patient receive Forteo 20 ug/day SQ . Adult patient ( age least 18 yr ) OI enrol treatment duration 18 month . Blood , urine , bone density/strength test do study ass efficacy safety .</detailed_description>
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Previous establish diagnosis Osteogenesis Imperfecta AND &gt; 2 previous adult fracture , AND/OR BMD lumbar spine , femoral neck total hip T score &lt; 2.0 Open epiphysis . History external beam radiation skeleton . Pagets disease . Bone metastases skeletal malignancy . Total lifetime exposure antiresorptive medication &lt; 90 day ( Primary Inclusion ) . Treatment antiresorptive medication 12 month proceed enrollment ( Secondary Inclusion ) . Women OI pregnant unwilling use 1 form contraception . Vitamin D insufficiency ( 25hydroxyvitamin D &lt; 15ng/ml )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Osteogenesis Imperfecta</keyword>
	<keyword>Brittle Bone Disease</keyword>
	<keyword>Fragility Fractures</keyword>
</DOC>